Angiogenesis inhibition and cell cycle arrest induced by treatment with Pseudolarix acid B alone or combined with 5-fluorouracil

Acta Biochimica et Biophysica Sinica

Volumn 44, Issue 6, 2012, Pages 490-502

  Liu, Jingtao ^a   Guo, Wei ^a   Xu, Bo ^a   Ran, Fuxiang ^a   Chu, Mingming ^a   Fu, Hongzheng ^a   Cui, Jingrong ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

5 fluorouracil; angiogenesis inhibition; cell cycle arrest; combination therapy; Pseudolarix acid B

Indexed keywords

ANGIOGENESIS INHIBITOR; DITERPENE; FLUOROURACIL; PSEUDOLARIC ACID B;

ANIMAL; ARTICLE; CELL CYCLE CHECKPOINT; CELL MOTION; DRUG EFFECT; DRUG SCREENING; HUMAN; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL CYCLE CHECKPOINTS; CELL MOVEMENT; DITERPENES; FLUOROURACIL; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; NEOVASCULARIZATION, PATHOLOGIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

PSEUDOLARIX;

EID: 84861905741     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gms029     Document Type: Article

References (24)

1. Bschof M, Abdollahi A, Gong P, Stoffegen C, Lipson KE, Debus JU and Weber KJ, et al. Triple combination of irradiation, chemotherapy (pemetrexed), and VEGF inhibition (SU5416) in human endothelial and tumor cells. Int J Radiat Oncol Biol Phys 2004, 60:1220-1232.
2. Harari PM and Huang SM. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 2001, 49:427-433.
3. Liu JT, Xu B, Li M, Zhou Y and Cui JR. Inhibition of angiogenesis by DADAG in vivo and in vitro. J Chin Pharmaceut Sci 2010, 19:177-185.
4. Bisacchi D, Benelli R, Vanzetto C, Ferrari N, Tosetti F and Albini A. Anti-angiogenesis and angioprevention: mechanisms, problems and perspectives. Cancer Detect Prev 2003, 27:229-238.
5. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
6. Jia L, Xu B, Guo W, Ge ZM, Li RT and Cui JR. Enhanced antitumor effect and mechanism of TM208 in combination with 5-fluorouracil in H22 transplanted mice. J Chin Pharmaceut Sci 2011, 20:615-626.
7. Li MH, Miao ZH, Tan WF, Yue JM, Zhang C, Lin LP and Zhang XW, et al. Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1alpha by promoting proteasome-mediated degradation. Clin Cancer Res 2004, 10:8266-8274.
8. Wong VK, Chiu P, Chung SS, Chow LM, Zhao YZ, Yang BB and Ko BC. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo. Clin Cancer Res 2005, 11:6002-6011.
9. Wang WC and Gu ZP. Efects of pseudolaric acld B on blood flows of endometrium and myometrium in pregnant rats. Acta Pharmacol Sin 1991, 12:423-425.
10. Tong YG, Zhang XW, Geng MY, Yue JM, Xin XL, Tian F and Shen X, et al. Pseudolarix acid B, a new tubulin-binding agent, inhibits angiogenesis by interacting with a novel binding site on tubulin. Mol Pharmacol 2006, 69:1226-1233.
11. Tan WF, Zhang XW, Li MH, Yue JM, Chen Y, Lin LP and Ding J. Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect. Eur J Pharmacol 2004, 499:219-228.
12. Jaffe EA, Nachman RL, Becker CG and Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973, 52:2745-2756.
13. Wang XH, Xu B, Liu JT and Cui JR. Effect of b-escin sodium on endothelial cells proliferation, migration and apoptosis. Vasc Pharmacol 2008, 49:158-165.
14. Kumar I, Staton CA, Cross SS, Reed MW and Brown NJ. Angiogenesis, vascular endothelial growth factor and its receptors in human surgical wounds. Br J Surg 2009, 96:1484-1491.
15. Ryan CJ, Lin AM and Small EJ. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale. Urol Oncol 2006, 24:250-253.
16. Bocci G, Falcone A, Fioravanti A, Orlandi P, Di Paolo A, Fanelli G and Viacava P. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer 2008, 98:1619-1629.
17. Huang CC, Wu MC, Xu GW, Li DZ, Cheng H, Tu ZX and Jiang HQ, et al. Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst 1992, 84:262-264.
18. Yin H, Xie F, Zhang J, Yang Y, Deng B, Sun J and Wang Q. Combination of interferon-α and 5-fluorouracil induces apoptosis through mitochondrial pathway in hepatocellular carcinoma in vitro. Cancer Lett 2011, 306:34-42.
19. Duan SW, Xu B, Chen YL, LI M, Fu HZ and Cui JR. Explore the mechanism of inhibitory effects of Pseudolaric acid B on MCF-7 cells by high content analysis. Prog Biochem Biophys 2010, 37:1313-1322.
20. Tseng YS, Tzeng CC, Chiu AW, Lin CH, Won SJ, Wu IC and Liu HS. Ha-ras overexpression mediated cell apoptosis in the presence of 5-fluorouracil. Exp Cell Res 2003, 288:403-414.
21. Alshenawy HA. Prognostic significance of vascular endothelial growth factor, basic fibroblastic growth factor, and microvessel density and their relation to cell proliferation in B-cell non-Hodgkin's lymphoma. Ann Diagn Pathol 2010, 14:321-327.
22. Toomey DP, Murphy JF and Conlon KC. COX-2, VEGF and tumour angiogenesis. Surgeon 2009, 7:174-180.
23. Hendriksen EM, Span PN, Schuuring J, Peters JP, Sweep FC, van der Kogel AJ and Bussink J. Angiogenesis, hypoxia and VEGF expression during tumour growth in a human xenograft tumour model. Microvesc Res 2009, 77:96-103.
24. Castedo M, Perfettini JL, Roumier T and Kroemer G. Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ 2002, 9:1287-1293.